Literature DB >> 21585290

Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus.

L Hopia1, M Thangarajh, M Khademi, A Laveskog, E Wallström, E Svenungsson, M Andersson.   

Abstract

OBJECTIVES: A proliferation-inducing ligand (APRIL) and B-cell activation factor (BAFF) are B-cell stimulation and survival molecules. We have investigated whether APRIL and/or BAFF activity is enhanced in the systemic and/or intrathechal compartment of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). In particular, the association between fatigue and APRIL/BAFF activity was investigated.
METHODS: Twenty-eight NPSLE patients were evaluated clinically, with sampling of cerebrospinal fluid (CSF) and blood, and magnetic resonance imaging (MRI). CSF and blood samples from 13 multiple sclerosis (MS) patients and 17 patients with other neurological diseases (OND) were used as controls. Protein levels of BAFF and APRIL were quantified in CSF and plasma, mRNA expression levels of BAFF and APRIL were determined in peripheral blood (PBMC) and CSF mononuclear cells (CSF-MC). The Fatigue Severity Scale (FSS) was used to quantify the degree of fatigue.
RESULTS: NPSLE patients had higher levels of APRIL in CSF as compared to OND (p < 0.01). No corresponding increase in APRIL mRNA levels was detected in CSF-MC. BAFF levels in plasma were higher in NPSLE than in OND (p < 0.001). BAFF mRNA expression in PBMC was also higher in NPSLE patients than in controls (p < 0.05). FSS scores in patients with NPSLE correlated significantly with APRIL levels in CSF.
CONCLUSIONS: Protein levels of APRIL in CSF were increased in NPSLE as compared to OND. Moreover, there was a positive correlation between CSF APRIL levels and fatigue. Our results suggest that APRIL and possibly also BAFF may be involved in the pathogenesis of NPSLE and in SLE-related fatigue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585290     DOI: 10.3109/03009742.2010.550900

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  Similarity of autoimmune diseases based on the profile of immune complex antigens.

Authors:  Miyako Baba; Kunihiro Ichinose; Mami Tamai; Atsushi Kawakami; Kaname Ohyama
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

Review 2.  Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus.

Authors:  Barbara Stypińska; Agnieszka Paradowska-Gorycka
Journal:  Int J Mol Sci       Date:  2015-10-13       Impact factor: 5.923

Review 3.  Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus.

Authors:  Sen Hee Tay; Anselm Mak
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

4.  Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study.

Authors:  Paula Gyllemark; Pia Forsberg; Jan Ernerudh; Anna J Henningsson
Journal:  J Neuroinflammation       Date:  2017-02-01       Impact factor: 8.322

Review 5.  Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.

Authors:  Julius Lindblom; Chandra Mohan; Ioannis Parodis
Journal:  Brain Sci       Date:  2022-01-30

6.  BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Anna L Travelstead; Jerry A Colliver; Jayne M Ness; Richard M Ransohoff
Journal:  J Neuroinflammation       Date:  2013-01-16       Impact factor: 8.322

Review 7.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.